First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS

NCT03231722 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

435

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Panitumumab
DRUG: Irinotecan
DRUG: Oxaliplatin
DRUG: l-leucovorin
DRUG: 5-fluorouracil

Sponsor

Gruppo Oncologico del Nord-Ovest